• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Flynn James E bought $37,499,993 worth of shares (4,290,617 units at $8.74) (SEC Form 4)

    2/16/24 2:37:50 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LRMR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Flynn James E

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Larimar Therapeutics, Inc. [ LRMR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    3. Date of Earliest Transaction (Month/Day/Year)
    02/16/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/16/2024 P 1,430,206 A $8.74 6,151,389 I Through Deerfield Private Design Fund III, L.P.(1)(2)
    Common Stock 02/16/2024 P 1,430,206 A $8.74 6,151,406 I Through Deerfield Private Design Fund IV, L.P.(1)(2)
    Common Stock 02/16/2024 P 1,430,205 A $8.74 4,207,982 I Through Deerfield Partners, L.P.(1)(2)
    Common Stock 4,721,197 I Through Deerfield Healthcare Innovations Fund, L.P.(1)(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Flynn James E

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Mgmt III, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Mgmt HIF, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Mgmt IV, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Mgmt L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Private Design Fund III, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Healthcare Innovations Fund, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    Deerfield Private Design Fund IV, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    1. Name and Address of Reporting Person*
    DEERFIELD PARTNERS, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    * Director by Deputization
    Explanation of Responses:
    1. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
    2. In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
    Remarks:
    Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.
    /s/ Jonathan Isler, Attorney-in-Fact 02/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LRMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LRMR

    DatePrice TargetRatingAnalyst
    1/29/2025$18.00Buy
    Truist
    10/16/2024$26.00Outperform
    Oppenheimer
    10/3/2024$22.00Outperform
    Wedbush
    10/2/2024$15.00Buy
    H.C. Wainwright
    9/4/2024$16.00Outperform
    Robert W. Baird
    4/3/2024$25.00Outperform
    Leerink Partners
    11/17/2023$4.50Neutral → Buy
    Citigroup
    10/19/2022$12.00Buy
    Guggenheim
    More analyst ratings